Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall

After rumors of stalled buyout talks between Merck and Seagen, perhaps a new Tukysa indication could reignite interest.

The FDA has granted Tukysa a priority review in combination with Genentech’s Herceptin for second-line HER2-positive metastatic colorectal cancer, the company revealed on Monday.